{"entity":{"id":"cristina-saura","kind":"person","name":"Cristina Saura","aka":[],"tldr":"Spanish breast oncologist leading DESTINY-Breast09, which moved trastuzumab deruxtecan into first-line HER2-positive disease.","summary":"Cristina Saura led NALA (neratinib plus capecitabine) and is a principal investigator of DESTINY-Breast09, the trial showing trastuzumab deruxtecan plus pertuzumab outperforms the CLEOPATRA regimen first line. She heads breast cancer at Vall d'Hebron, is active in the SOLTI cooperative group, and works on ctDNA and brain-metastasis strategies in HER2-positive disease.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Saura%20C%5BAuthor%5D%20breast%20HER2"}],"tags":["breast","her2","adc"],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":["adc"],"targets":["her2"],"drugs":["trastuzumab-deruxtecan"],"companies":["solti"],"institutions":["vall-dhebron"],"pathways":[],"terms":[],"trials":["destiny-breast09"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head of the Breast Cancer Unit, Vall d'Hebron University Hospital and VHIO","institutionId":"vall-dhebron","specialisms":["HER2-positive breast cancer","Antibody-drug conjugates","Tyrosine kinase inhibitors","Brain metastases"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Saura%20C%5BAuthor%5D%20breast%20HER2"}],"papers":[{"title":"Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with two or more HER2-directed regimens (NALA)","journal":"JCO","year":2020,"doi":"10.1200/JCO.20.00147"},{"title":"Trastuzumab deruxtecan plus pertuzumab for first-line HER2-positive advanced breast cancer (DESTINY-Breast09)","journal":"NEJM","year":2025}]},"route":"/people/cristina-saura/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}],"drug":[{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"}],"company":[{"id":"solti","kind":"company","name":"SOLTI Cancer Research Group","route":"/companies/solti/"}],"institution":[{"id":"vall-dhebron","kind":"institution","name":"Vall d'Hebron University Hospital / VHIO","route":"/institutions/vall-dhebron/"}],"trial":[{"id":"destiny-breast09","kind":"trial","name":"DESTINY-Breast09","route":"/trials/destiny-breast09/"},{"id":"nala","kind":"trial","name":"NALA","route":"/trials/nala/"}]}}